Serum-Stable Alpha v Beta 6 Integrin Ligands for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a challenge in delivering therapeutically effective compounds specifically to cells or tissues expressing integrin alpha-v beta-6, particularly for targeting cancer cells, due to the lack of stable and effective ligands that can selectively bind to integrin alpha-v beta-6 and facilitate the entry of therapeutic cargo molecules through receptor-mediated endocytosis or pinocytosis.
Innovation Solution
Development of novel, synthetic αvβ6 integrin ligands that are stable in serum and have specific affinity for integrin αvβ6, allowing them to be conjugated with cargo molecules for targeted delivery to cells expressing αvβ6 integrin, including the use of oligonucleotide-based compounds like RNAi agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional targeting ligands are used, then delivery to target cells may be achieved, but the ligands lack stability in serum and cannot selectively bind to integrin alpha-v beta-6
Solution Approach 1:
The patent modifies the chemical structure of targeting ligands by changing parameters such as molecular weight, hydrophobicity, and functional group composition to create ligands that are both stable in serum and selectively bind to integrin alpha-v beta-6. The synthetic ligands incorporate specific chemical moieties that enhance serum stability while maintaining or improving binding affinity for the target integrin.
Solution Approach 2:
The patent employs composite ligand structures that combine multiple functional components - including cell-penetrating peptides, targeting moieties specific to integrin alpha-v beta-6, and serum stability-enhancing groups. These composite structures achieve both serum stability and selective binding by integrating the strengths of different molecular components into a single functional ligand system.
2Manufacturing precision
If non-specific delivery methods are used, then cargo molecules can be delivered broadly, but cannot achieve specific delivery to cells expressing integrin alpha-v beta-6
Solution Approach 1:
The patent divides the delivery system into separate functional modules: a targeting ligand portion specific to integrin alpha-v beta-6, a linker portion, and a cargo molecule portion. This segmentation allows each component to be optimized independently for its specific function while maintaining overall system simplicity through modular assembly via standard conjugation chemistries.
Solution Approach 2:
The patent uses designed linker molecules as intermediaries between the targeting ligand and cargo molecule. These intermediaries facilitate controlled conjugation while maintaining the functionality of both the targeting ligand and cargo, enabling specific delivery without requiring complex integrated systems.
3Stability of the object's composition
If stable ligands are used, then serum stability is improved, but affinity and specificity for integrin alpha-v beta-6 may be reduced
Solution Approach 1:
The patent applies local quality by designing ligands where specific local regions maintain high affinity for integrin alpha-v beta-6 binding sites while other regions provide serum stability. The ligand structure contains distinct functional domains: a binding domain with high specificity for the integrin receptor and stabilizing domains that protect against serum degradation, allowing both properties to coexist without compromising either.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The αvβ6 integrin ligands enable efficient and specific delivery of therapeutic cargo molecules to cells expressing integrin αvβ6, potentially inhibiting target gene expression, thereby treating diseases mediated by αvβ6 integrin expression, such as cancer.
Implementation Method 1
The αvβ6 integrin ligands disclosed herein are stable in serum and have affinity for, and can bind with specificity to, αvβ6 integrins
Implementation Method 2
facilitate the entry of the therapeutic into the cell through receptor-mediated endocytosis, pinocytosis, or by other means
Data Source
AI summary
Synthetic αvβ6 integrin ligands of Formula I having serum stability and affinity for integrin αvβ6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin αvβ6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include αvβ6 integrin ligands and methods of use are also described.